News Sentiment

JUNS sentiment intelligence

Jupiter Neurosciences, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.17 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-9.2% over one week, -27.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -9.2% Price reacting lower
Trend fit Trend inactive -27.5% over four weeks
Fair value -88.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 38
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 15
The Motley Fool 7
Stock Titan 6
TradingView 6
Investing News Network 2
GlobeNewswire 2
Moomoo 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 41
Earnings 16
Deals and strategy 8
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 66
Mugglehead Investment Magazine Direct company coverage

CNS drug specialist Jupiter Neuro signs MDMA deal with PharmAla Biotech

Jupiter Neurosciences Inc. has secured exclusive U.S. rights to Pharmala Biotech's ALA-002, an MDMA formulation for neuropsychiatric conditions, in a deal valued up to US$100 million. This agreement expands Jupiter's focus from neurodegeneration to also include neuropsychiatric d

Tone
Positive 66/100
Event
Deals and strategy
Published
22 Jul 2026 17:40
Source
Mugglehead Investment Magazine
EIN News Direct company coverage

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002

Jupiter Neurosciences (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for perpetual exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation valued at up to $100 million. This acquisition expands Jupiter into a dual c

Tone
Positive 73/100
Event
Deals and strategy
Published
22 Jul 2026 15:40
Source
EIN News
MSN Direct company coverage

Jupiter Neurosciences acquires US rights to ALA-002 in deal worth up to $100M

Jupiter Neurosciences has acquired the U.S. rights to ALA-002, a drug developed by Saneron CCEL Therapeutics for neurological and neuro-ophthalmic disorders, in a deal potentially worth up to $100 million. The agreement includes an upfront payment, milestone payments, and royalti

Tone
Positive 71/100
Event
Deals and strategy
Published
22 Jul 2026 15:40
Source
MSN
BioXconomy Direct company coverage

Jupiter Neurosciences licenses MDMA drug ALA-002

Jupiter Neurosciences has licensed exclusive US rights to PharmAla Biotech Holdings' MDMA drug ALA-002, intended for neuropsychiatric disorders like PTSD and anxiety. The deal includes an upfront payment of $3.3 million and potential milestones up to $20 million upon FDA approval

Tone
Neutral 50/100
Event
Deals and strategy
Published
22 Jul 2026 15:40
Source
BioXconomy
Investing News Network Direct company coverage

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002

PharmAla Biotech Holdings Inc. has announced a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive, perpetual U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla's lead drug candidate. The deal is valued at up to approximately

Tone
Positive 73/100
Event
Deals and strategy
Published
21 Jul 2026 21:40
Source
Investing News Network
Stock Titan Direct company coverage

Jupiter Neurosciences (Nasdaq: JUNS) to license ALA-002 in US

Jupiter Neurosciences (Nasdaq: JUNS) has entered into a definitive Strategic Asset License Agreement with PharmAla Biotech Holdings Inc., securing exclusive U.S. rights to develop, manufacture, and commercialize ALA-002 for human therapeutic uses. The agreement includes an upfron

Tone
Positive 74/100
Event
Market update
Published
21 Jul 2026 20:10
Source
Stock Titan
Benzinga Direct company coverage

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

This article identifies 12 healthcare stocks that are experiencing significant movement in pre-market trading on Tuesday. It lists both gainers, such as Jupiter Neurosciences and Imunon, and losers, including Zhengye Biotechnology and Lisata Therapeutics, along with their respect

Tone
Positive 70/100
Event
Market update
Published
21 Jul 2026 12:10
Source
Benzinga
GlobeNewswire Direct company coverage

PharmAla Biotech Executes Definitive License Agreement

PharmAla Biotech has entered into a definitive license agreement with Jupiter Neurosciences, granting Jupiter exclusive U.S. rights to develop, manufacture, and commercialize ALA-002, PharmAla’s lead drug candidate. The deal is valued at up to approximately US$100 million, includ

Tone
Positive 73/100
Event
Deals and strategy
Published
21 Jul 2026 11:10
Source
GlobeNewswire
Market source Direct company coverage

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has signed a definitive license agreement with PharmAla Biotech Holdings Inc. for exclusive U.S. rights to ALA-002, a patented, non-racemic MDMA formulation. The transaction is valued at up to $100 million, including milestone payments,

Tone
Positive 72/100
Event
Market update
Published
21 Jul 2026 11:10
Source
Market source
Stock Titan Direct company coverage

PharmAla Retains ALA-002 Rights Outside U.S. in Jupiter License

PharmAla Biotech has granted Jupiter Neurosciences exclusive U.S. rights to its lead drug candidate, ALA-002, in a deal worth up to $100 million. PharmAla retains all international rights to ALA-002 and will receive an upfront payment, milestone payments, and royalties on U.S. ne

Tone
Positive 72/100
Event
Deals and strategy
Published
21 Jul 2026 11:10
Source
Stock Titan
Market source Direct company coverage

Jupiter Neurosciences Signs ALA-002 License Agreement Worth Up to $100 Million (NASDAQ:JUNS)

Jupiter Neurosciences (NASDAQ:JUNS) has signed an exclusive U.S. licensing agreement with PharmAla Biotech Holdings for ALA-002, a clinical-stage psychedelic therapeutic candidate, valued at up to $100 million. This deal transforms Jupiter into a dual clinical-stage CNS company,

Tone
Positive 74/100
Event
Deals and strategy
Published
21 Jul 2026 10:27
Source
Market source
Stock Titan Direct company coverage

Insider at Jupiter Neurosciences (JUNS) unlocks 1.01M shares

Jupiter Neurosciences' Chief Scientific Officer and director, Marshall A. Hayward, exercised derivative awards, converting 1,014,195 shares into common stock. These transactions included restricted stock awards and stock options, increasing his direct common stock holdings to 2,9

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 09:40
Source
Stock Titan
TradingKey Direct company coverage

Jupiter Neurosciences Inc (JUNS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Jupiter Neurosciences Inc (JUNS), highlighting its current price momentum, support and resistance levels, and indicator and moving average signals. The stock currently has a price momentum score of 5.55, trading between resistance at

Tone
Negative 18/100
Event
Market update
Published
11 Jul 2026 06:10
Source
TradingKey
The Globe and Mail Direct company coverage

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has appointed Dr. Tomas J. Philipson, a distinguished health care economist and former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson will serve on both

Tone
Positive 72/100
Event
Market update
Published
09 Jul 2026 07:09
Source
The Globe and Mail
The Motley Fool Direct company coverage

Why Figma Stock Lost 29% in June

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 07:00
Source
The Motley Fool
Moomoo Direct company coverage

Jupiter Neurosciences Strengthens Bd With Appointment of Dr. Tomas J. Philipson

Jupiter Neurosciences has announced the appointment of Dr. Tomas J. Philipson to its Board of Directors. Dr. Philipson brings extensive experience in economics, healthcare, and public policy, having served in significant roles including former Acting Chairman of the Council of Ec

Tone
Positive 77/100
Event
Market update
Published
08 Jul 2026 06:10
Source
Moomoo
Investing.com Direct company coverage

Jupiter Neurosciences appoints Tomas Philipson to board

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) has appointed Dr. Tomas J. Philipson, a former acting chairman of the White House Council of Economic Advisers, to its Board of Directors, where he will serve on the Audit and Compensation Committees. Dr. Philipson, a health care economis

Tone
Positive 70/100
Event
Market update
Published
07 Jul 2026 13:41
Source
Investing.com
Quiver Quantitative Direct company coverage

Jupiter Neurosciences Appoints Former White House CEA Acting Chairman Tomas J. Philipson to Board of Directors

Jupiter Neurosciences, Inc. has appointed Tomas J. Philipson, Ph.D., former Acting Chairman of the White House Council of Economic Advisers, to its Board of Directors, effective June 26, 2026. Dr. Philipson, a distinguished health care economist, will bring extensive experience i

Tone
Positive 74/100
Event
Market update
Published
07 Jul 2026 13:01
Source
Quiver Quantitative